Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial.
about
Renal protection in cardiovascular surgeryRisk prediction models for contrast induced nephropathy: systematic reviewSide effects of radiographic contrast media: pathogenesis, risk factors, and preventionBridging Translation by Improving Preclinical Study Design in AKIReducing contrast-induced acute kidney injury using a regional multicenter quality improvement interventionDrug-induced impairment of renal function.Mitochondrial reactive oxygen species at the heart of the matter: new therapeutic approaches for cardiovascular diseases.Delayed Consequences of Acute Kidney Injury.Bridging translation for acute kidney injury with better preclinical modeling of human diseaseRenal dysfunction and the associated decrease in survival after elective endovascular aneurysm repair.Preclinical Studies of a Kidney Safe Iodinated Contrast Agent.Effect of remote ischaemic conditioning on contrast-induced nephropathy in patients undergoing elective coronary angiography (ERICCIN): rationale and study design of a randomised single-centre, double-blind placebo-controlled trial.Balanced crystalloids versus saline in the intensive care unit: study protocol for a cluster-randomized, multiple-crossover trial.Challenges and advances in the treatment of AKI.Critical care in the emergency department: acute kidney injury.A systematic review and meta-analysis of the efficacy and safety of N-acetylcysteine in preventing aminoglycoside-induced ototoxicity: implications for the treatment of multidrug-resistant TB.Identification of Major Adverse Kidney Events Within the Electronic Health Record.Use of Radiocontrast Agents in CKD and ESRD.Understanding and preventing contrast-induced acute kidney injury.Balanced Crystalloids versus Saline in the Intensive Care Unit. The SALT Randomized Trial.Contemporary practice patterns related to the risk of acute kidney injury in the catheterization laboratory: Results from a survey of Society of Cardiovascular Angiography and Intervention (SCAI) cardiologists.Pyridoxamine reduces postinjury fibrosis and improves functional recovery after acute kidney injuryCandidate Surrogate End Points for ESRD after AKI.Dose escalation study of intravenous and intra-arterial N-acetylcysteine for the prevention of oto- and nephrotoxicity of cisplatin with a contrast-induced nephropathy model in patients with renal insufficiency.Acute kidney injury: Clinical trials in AKI: is the end in sight?N-acetylcysteine in contrast-induced acute kidney injury: clinical use against principles of evidence-based clinical medicine!Translating Knowledge Into Therapy for Acute Kidney Injury.End Points for Clinical Trials in Acute Kidney Injury.Contrast-Induced Nephropathy: Update on the Use of Crystalloids and Pharmacological Measures.
P2860
Q26753127-4B1C96BC-D8A0-40C1-AD46-0F49E584B22BQ26796473-F762B56F-4697-4502-8FD6-00A77C74C064Q26853304-F7CA3806-63A6-414F-BAE2-D94C2E8BB7B8Q28084530-A0317436-CC9D-48B7-B3AC-0B1508AF2F21Q28602648-EB36AEBF-4E52-4848-A5DC-B820527E3725Q34731462-5C0C9748-F62A-4713-9C04-9F8C112A3C54Q35645530-DAB103B0-49A4-4F33-9E5B-A203A45F92E1Q36848250-E5DBBB14-4CA7-41AB-A74F-D28FBE67D6F5Q36957116-327D75C1-4191-4DB8-AD1A-F91F9C5D81E8Q37365608-B6E2E1FA-A615-4BDD-A855-CC93DD5770E3Q37375593-6FFAF191-489D-46B8-949F-705451C36338Q37608257-A5B17C6D-CBBE-4DDC-B2C3-91AADCBB0B05Q37708328-76CDC460-51A9-451B-8927-F65AFAFDC75DQ37733599-DB00AF0B-3859-4CC4-90B4-84015BADDAA3Q38476890-FDF0DF56-6EA0-4DE1-A96D-E7B00B86BD81Q38582633-C11653F9-E344-447B-BB4D-75A40D3DF9EAQ38846444-1AF4854D-120C-4525-9750-F7BEBAE730F2Q38851069-3EFD854E-6CC5-4CBB-AECC-C355509CF61BQ39110308-08C7AA31-89F5-4D4F-8D3A-715C53515C45Q39282707-3F9795C5-8D78-4B3E-9A1D-0574E716D10BQ39674875-6B50FD3E-B740-4B55-9AE0-B8E1F4646EE4Q39754544-07473624-9477-4E83-806F-04DD151B0BE0Q40921568-EF751303-E4B2-464D-A002-2A979ECD06BEQ42281143-BFE277A5-03F2-4BF6-90B0-2A0AEDE9DE10Q46167149-3D40262F-3385-4608-B8AA-1EEDA20D0A46Q46320506-9E4E924B-1565-4160-BFFD-022091F87618Q47226520-7EAE88AF-78E9-43CD-A66D-DADBC6B0DCD0Q50350882-DF1B7D2D-5740-4885-AA2D-A00E3D57BDACQ55243370-F67CADD2-E782-4D70-A0C7-122261A767F7
P2860
Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Prevention of contrast-induced ...... g angiography (PRESERVE) trial
@nl
Prevention of contrast-induced ...... angiography (PRESERVE) trial.
@ast
Prevention of contrast-induced ...... angiography (PRESERVE) trial.
@en
type
label
Prevention of contrast-induced ...... g angiography (PRESERVE) trial
@nl
Prevention of contrast-induced ...... angiography (PRESERVE) trial.
@ast
Prevention of contrast-induced ...... angiography (PRESERVE) trial.
@en
prefLabel
Prevention of contrast-induced ...... g angiography (PRESERVE) trial
@nl
Prevention of contrast-induced ...... angiography (PRESERVE) trial.
@ast
Prevention of contrast-induced ...... angiography (PRESERVE) trial.
@en
P2093
P2860
P50
P3181
P356
P1476
Prevention of contrast-induced ...... g angiography (PRESERVE) trial
@en
P2093
Chirag R Parikh
Glenn M Chertow
Grant D Huang
James Kaufman
Joanne Lee
Kendrick A Shunk
Martin Gallagher
Mary T Brophy
Michael J Fine
Peter A McCullough
P2860
P304
P3181
P356
10.2215/CJN.11161012
P407
P577
2013-05-09T00:00:00Z